-
Aslan Pharmaceuticals Shares Are Trading Higher On Positive ASLAN004 Data In Atopic Dermatitis
Monday, March 1, 2021 - 8:18am | 234Aslan Pharmaceuticals Ltd (NASDAQ: ASLN) announces positive interim unblinded data from its ongoing Phase 1 study evaluating ASLAN004 to treat moderate to severe atopic dermatitis (AD). Subcutaneous delivery of ASLAN004 was shown to be well tolerated across all doses (200mg, 400mg, and...
-
Sanofi/Regeneron's DUPIXENT Wins Canada Approval For Atopic Dermatitis In Children Aged 6-11
Tuesday, February 23, 2021 - 11:33am | 246Health Canada has approved Sanofi’s SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) DUPIXENT (dupilumab injection) for the treatment of moderate-to-severe atopic dermatitis in children aged six to 11 years whose disease is not adequately...
-
FDA Accepts Incyte's Ruxolitinib Cream US Application For Chronic Skin Disease
Friday, February 19, 2021 - 10:32am | 160Under Priority Review status, the FDA has accepted Incyte Corporation's (NASDAQ: INCY) marketing application for review seeking approval for ruxolitinib cream. Ruxolitinib is a selective JAK1/JAK2 inhibitor as a treatment for atopic dermatitis, a type of eczema...
-
Expectations For Regeneron No Longer Realistic; Analyst Downgrades
Tuesday, August 1, 2017 - 8:58am | 334Analysts at Baird Equity Research turned bearish on Regeneron Pharmaceuticals Inc (NASDAQ: REGN) as investor expectation for a recently launched drug may be too high. The firm's Brian Skorney downgrades Regeneron's stock rating from Neutral to Underperform with an unchanged $408 price target....
-
Anacor Shares Surge To All-Time Highs After Phase 3 Trials Of Eczema Drug
Monday, July 13, 2015 - 2:29pm | 529In a public conference call on Monday, Anacor Pharmaceuticals Inc (NASDAQ: ANAC) executives announced the results of two Phase 3 trials for a topical drug to treat atopic dermatitis, more commonly known as eczema. The treatment came in the form of a topical ointment, crisaborole. Atopic dermatitis...